A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 inhibitor) in Combination with Vemurafenib (BRAF Inhibitor) in Patients with Advanced Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
At a glance
- Drugs Crizotinib (Primary) ; Sorafenib (Primary) ; Vemurafenib (Primary)
- Indications Cancer
- Focus Adverse reactions
- 11 May 2018 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2021.
- 21 Mar 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.